Administered subcutaneously at 0.3 mg/kg/min through mini pumps for 33 days, Iloprost shows significant anti-metastatic effects in a rat model with spontaneous metastasis^[2].

Iloprost given at 0.2 mg/kg/day intraperitoneally for 10 days mitigates the effects of hyperoxia and lowers inflammation in the lungs of newborn mice, with Cyclooxygenase-2 (COX-2/PTGS2) playing a role in hyperoxia-induced damage^[3].

When administered intravenously or intraperitoneally at 0.2 mg/kg, Iloprost has a short half-life, leading to its frequent administration via inhalation every 2-4 hours in treatments^[4].

Prostacyclin (PGI2) is produced in the oviductal fluid and promotes embryo development^[1].

Acting as an analog of PGI2, Iloprost influences the maturation and developmental competence of bovine oocytes^[1].

At a concentration of 0.5 μM over 22-24 hours, Iloprost increases both the rate of blastocyst formation in bovine embryos and the proportion of those that expand^[1].

In the same conditions, Iloprost enhances the maturation rates and cumulus cell expansion of bovine oocytes and boosts mRNA expression of genes associated with cumulus expansion^[1].

Also, Iloprost at 0.5 μM for 22-24 hours decreases apoptosis in cumulus-oocyte complexes (COCs) and fosters an anti-apoptotic environment in gene transcription relevant to apoptosis, such as BAX and BCL2^[1].